EXELIXIS, INC. (NASDAQ:EXEL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
adopted the Exelixis, Inc. 2016 Inducement Award Plan (the
Inducement Plan) to which Exelixis reserved 1,500,000 shares of
Exelixis common stock for issuance under the Inducement Plan. The
only persons eligible to receive grants of Awards under the
Inducement Plan are individuals who satisfy the standards for
inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the
related guidance under Nasdaq IM 5635-1 that is, generally, a
person not previously an employee or director of Exelixis, or
following a bona fide period of non-employment, as an inducement
material to the individual’s entering into employment with
Exelixis. An Award is any right to receive Exelixis common stock to
the Inducement Plan, consisting of nonstatutory stock options,
stock appreciation rights, restricted stock awards, restricted
stock unit awards, or any other stock award. On November 18, 2016,
the Board of Directors of Exelixis also adopted forms of agreements
for use with the Inducement Plan.
complete, and reference is made to the Inducement Plan filed as
Exhibit 10.1 hereto for a full description of the terms of the
Inducement Plan. The forms of agreements for use with the
Inducement Plan are attached as Exhibit 10.2 hereto.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
10.1
|
|
2016 Inducement Award Plan
|
|
10.2
|
|
Forms of Agreements used in Connection with the 2016
Inducement Award Plan |
About EXELIXIS, INC. (NASDAQ:EXEL)
Exelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins. EXELIXIS, INC. (NASDAQ:EXEL) Recent Trading Information
EXELIXIS, INC. (NASDAQ:EXEL) closed its last trading session down -0.92 at 16.25 with 5,121,547 shares trading hands.
